
Why Is Aurobindo Pharma Share Price Falling? Key Reasons and Share Price Target
Tue Apr 14 2026

Aurobindo Pharma (NSE: AUROPHARMA) share price has fallen -28% from its 52-week high of Rs 1,600 to Rs 1,150 — making it one of the most-searched stocks on investor platforms in April 2026. This analysis covers the key reasons for the fall, financial performance, technical levels, and the Aurobindo Pharma share price target for 2026.
Click Here — Get Free Investment Predictions on Univest.
About Aurobindo Pharma
Aurobindo Pharma is India’s second-largest pharma exporter — with the US market at 48% of revenue and a portfolio of 600+ FDA-approved products. API self-manufacturing gives Aurobindo significant cost advantage.
Why Is Aurobindo Pharma Share Price Falling? Key Reasons
Tap to Access Best Research Pieces on Univest.
1. Market Valuation Reset
US market consolidation — fewer branded-to-generic conversion opportunities.
2. Sector Headwinds
Injectable business ramp slower than expected — capacity added but approvals pending.
3. Company-Specific Pressure
Promoter Narayanaswamy Reddy family governance questions — historical precedent creates institutional caution.
4. Institutional Sentiment
R&D pipeline differentiation limited — mostly solid oral dosage generics.
Financial Performance & Technical Signals
| Parameter | Value |
| CMP | Rs 1,150 |
| 52-Week High | Rs 1,600 |
| 52-Week Low | Rs 1,050 |
| Market Cap | Rs 67,000 Cr |
| Trailing P/E | 16x |
| Analyst Target (Base) | Rs 1,350 |
| Analyst Target (Bull) | Rs 1,550 |
| Upside to 12M Target | 17–35% |
Track Aurobindo Pharma live on the Univest Screener — real-time fundamentals and analyst ratings.
Download the Univest iOS App or Univest Android App for live Aurobindo Pharma price and SEBI-registered research.
Aurobindo Pharma Share Price Target
Subscribe to Univest Pro for Premium Stock Research on Aurobindo Pharma.
12-Month Analyst Consensus Target
The analyst consensus 12-month target for Aurobindo Pharma is Rs 1,350 to Rs 1,550 — implying 17–35% upside from the current price of Rs 1,150. These are analyst projections and not guaranteed returns.
Recovery Catalysts
Cheapest large-cap pharma at 16x. Injectable capacity — 200 million vials — coming online.
Aurobindo Pharma Share Price Target Analysis
Short-term Rs 1,250–1,350; 12-month Rs 1,350–1,550; long-term Rs 1,800–2,100.
Conclusion
Aurobindo Pharma at Rs 1,150 has corrected -28% from its 52-week high of Rs 1,600. The reasons for the fall are specific and identifiable — us market consolidation — fewer branded-to-generic conversion opportunities. The 12-month analyst consensus target of Rs 1,350–Rs 1,550 implies 17–35% upside when the recovery catalysts materialise.
This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.
For more analysis, visit Univest Blogs.
Frequently Asked Questions
Q: Why is Aurobindo Pharma share price falling?
Aurobindo Pharma fell -28% from its 52-week high of Rs 1,600 to Rs 1,150. Key reasons: US market consolidation — fewer branded-to-generic conversion opportunities and Injectable business ramp slower than expected — capacity added but approvals pending.
Q: What is Aurobindo Pharma share price target 2026?
Analyst consensus 12-month target is Rs 1,350–Rs 1,550 — implying 17–35% upside from Rs 1,150. Not guaranteed returns.
Q: Is Aurobindo Pharma a buy at current levels?
This article does not constitute investment advice. Consult a SEBI-registered financial advisor before investing.
Q: What are the key recovery catalysts for Aurobindo Pharma?
Primary recovery catalysts: Cheapest large-cap pharma at 16x.
Q: What is Aurobindo Pharma’s market cap?
Aurobindo Pharma market cap is Rs 67,000 Cr at the current price of Rs 1,150.
Q: What is Aurobindo Pharma’s P/E ratio?
Aurobindo Pharma trailing P/E is 16x as of April 2026.
Q: What are the risks of investing in Aurobindo Pharma now?
Key risks: valuation at 16x P/E, sector headwinds, and macro uncertainty. Consult a SEBI-registered advisor.
Q: What is the long-term outlook for Aurobindo Pharma?
Short-term Rs 1,250–1,350; 12-month Rs 1,350–1,550; long-term Rs 1,800–2,100. Full details in the share price target section above.
Recent Articles
Why is KRBL Share Price Falling? Check Next Share Price Target
Why is Reliance Infrastructures Share Price Falling? Check Next Share Price Target
Why is Mahanagar Gas Share Price Falling? Check Next Share Price Target
Why is Happiest Minds Share Price Falling? Check Next Share Price Target
Related Posts
BLS International Services Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
BLS E-Services Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Hi-Tech Pipes Q4 Results 2026: Date, Revenue, PAT And Analyst Outlook
Bliss GVS Pharma Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
HFCL Q4 Results 2026: Date, Revenue, PAT And Analyst Outlook

